10.3760/cma.j.issn.1673-422X.2015.04.019

Abstract

Abstract: 【Abstract】Gastrointestinal neuroendocrine tumor (GI-NET) originates from peptide neurons and neuroendocrine cells in gastrointestinal tract, and secrets peptide hormones, leading to carcinoid syndrome which rarely happens in clinical practice. Because of the improvement of diagnostic method and understanding of this rare disease, the morbidity is rising in recent years. The main treatments of GINET are surgery and comprehensive therapy, consisting of chemotherapy and targeted therapy.

Key words: Gastrointestinal tract, Neuroendocrine tumors, Diagnostic evaluation, Therapeutics

Sheng-Neng-Quan-；Yang-Yi-；Wang-Zhi-Gang. 10.3760/cma.j.issn.1673-422X.2015.04.019[J]. Journal of International Oncology, 2015, 42(4): 309-312.

References

［1］ Oberndorfer S. Karzinoide tumoren des dunndarms［J］. Frankf Z Pathol, 1907, 1: 426432. ［2］ Modlin IM, Lye KD, Kidd M. A 5decade annlysis of 13,715 carcinoid tumors［J］. Cancer, 2003, 97(4): 934959. ［3］ Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 118. ［4］ Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis［J］. J Gastroenterol, 2015, 50(1): 5864. ［5］ Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nationwide cancer registrybased study［J］. PLoS One, 2013, 8(4): e62487. ［6］ Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems［J］. Pancreas, 2010, 39(6): 707712. ［7］ Pape UF, Berndt U, MüllerNordhorn J, et al. Prognostic factors of longterm outcome in gastroenteropancreatic neuroendocrine tumours［J］. Endocr Relat Cancer, 2008,15(4): 10831097. ［8］ Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 111314. ［9］ Dronamraju SS, Joypaul VB. Management of gastrointestinal carcinoid tumours  10 years experience at a district general hospital［J］. J Gastrointest Oncol, 2012, 3(2): 120129. ［10］ Gnanaseqaran G, O′Doherty MJ. Imaging neuroendocrine tumours with radionuclide techniques［J］. Minerva Endocrinol, 2008, 33(2):105126. ［11］中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识［J］. 中华病理学杂志, 2011, 40(4): 257262. ［12］ Knigge U, Hansen CP. Surgery for GEPNETs［J］. Best Pract Res Clin Gastroenterol, 2012, 26(6): 819831. ［13］ Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study［J］. Endocr Relat Cancer, 2009, 16(3): 885894. ［14］ Scherübl H, Jensen RT, Cadiot G, et al. Management of early gastrointestinal neuroendocrine neoplasms［J］. World J Gastrointest Endosc, 2011, 3(7): 133139. ［15］ Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 501513. ［16］ Ahn HK, Choi JY, Kim KM, et al. Phase Ⅱ study of pazopanib monotherapy in mentastatic gastroenteropancreatic neuroendocrine tumours［J］. Br J Cancer, 2013, 109(6): 14141419. ［17］ Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 514523. ［18］ Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors［J］. World J Gastroenterol, 2010, 16(24): 29632970. ［19］ Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors［J］. N Engl J Med, 2014, 371(3): 224233. ［20］ Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: welldifferentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum［J］. Pancreas, 2010, 39(6): 753766. ［21］ Castao JP, Sundin A, Maecke HR, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges［J］. Cancer Metastasis Rev, 2014, 33(1): 353359. ［22］ Platanias LC. Mechanisms of typeⅠ and typeⅡinterferonmediated signaling［J］. Nat Rev Immunol, 2005, 5(5): 375386. ［23］ berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Practice for diagnosis, treatment and followup［J］. Ann Oncol, 2012, 23 Suppl 7: vii124130. ［24］ Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin［J］. Endocr Relat Cancer, 2010, 17(1): R7590. ［25］ Casciano R, Wang X, Stern L, et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors［J］. Pancreas, 2013, 42(2): 339347. ［26］ Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)［J］. Gut, 2012, 61(1): 632.

[1]	Wang Jun, Jia Xiuhong. TGF-β/Smad signal pathway and acute leukemia [J]. Journal of International Oncology, 2023, 50(8): 498-502.
[2]	Huang Rui, Zhang Yunqing. Clinical efficacy of anlotinib monotherapy in second-line treatment of extensive stage small cell lung cancer with poor PS score [J]. Journal of International Oncology, 2023, 50(12): 705-710.
[3]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[4]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[5]	Xu Hangcheng, Wu Yun, Wang Jiayu. Research progress of breast cancer with low HER2 expression [J]. Journal of International Oncology, 2022, 49(9): 513-516.
[6]	Zhou Xinyu, Jia Xiuhong. Research progress of ferroptosis in the treatment of leukemia [J]. Journal of International Oncology, 2022, 49(12): 759-762.
[7]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[8]	Zhang Dandan, Yue Hongyun, Zhang Baihong. Adaptive therapy of human cancers: targeting cancer evolution [J]. Journal of International Oncology, 2020, 47(6): 368-371.
[9]	Zhang Baihong, Yue Hongyun. Application of selective CDK4/6 inhibitors in solid cancers therapy [J]. Journal of International Oncology, 2019, 46(6): 350-357.
[10]	Mo Qiuping, Chen Yiding, Wang Xiaochen, . Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer [J]. Journal of International Oncology, 2019, 46(10): 617-619.
[11]	Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen. Treatment progress of intrahepatic cholangiocarcinoma [J]. Journal of International Oncology, 2016, 43(1): 60-63.
[12]	HE Chun-Xiao, SONG Zheng-Bo, ZHANG Yi-Ping. Impact and treatment of chemotherapy-induced anemia on lung cancer patients [J]. Journal of International Oncology, 2013, 40(4): 278-283.
[13]	FU Chun. Application of diffusion-weighted imaging in the diagnosis and treatment of cervical cancer [J]. Journal of International Oncology, 2012, 39(6): 449-452.
[14]	ZHOU Shi-Qiu, LOU Shi-Feng, LUO Yun. Allogeneic stem cell transplantation in multiple myeloma [J]. Journal of International Oncology, 2012, 39(4): 301-304.